Amgen (AMGN) Teze Still on Track Despite Missed OCS-Sparing Claim, PT Adjusted to $266 - Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Jay Olson lowered the price target on Amgen (NASDAQ: AMGN) to $266.00 (from $274.00) while maintaining an Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
